ALLMedicine™ Gastrointestinal Hemorrhage Center

Jun 23rd, 2022 - Sepsis represents the most common cause of childhood mortality worldwide. In the United States alone, 200 cases of pediatric sepsis are diagnosed each day, with an associated hospital mortality rate of 5-10% and health care expenditures now approa...

Jun 11th, 2022 - We summarized the clinical features of acute necrotizing encephalopathy (ANE) in children. Clinical data of 14 children with ANE at one center from January 2017 to January 2020 were retrospectively analyzed. ANE severity score (ANE-ss) was used to...

Jun 7th, 2022 - Background Toxic epidermal necrolysis (TEN) is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible...

Jun 7th, 2022 - Background Toxic epidermal necrolysis (TEN) is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible...

Jun 7th, 2022 - Background Toxic epidermal necrolysis (TEN) is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible...

Sep 30th, 2015 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH). Main Recommendations MR1. ESGE recommends im...

Jun 23rd, 2022 - Sepsis represents the most common cause of childhood mortality worldwide. In the United States alone, 200 cases of pediatric sepsis are diagnosed each day, with an associated hospital mortality rate of 5-10% and health care expenditures now approa...

May 19th, 2022 - Anemia is one of the most common conditions encountered critically ill patients. Various mechanisms can put these patients at risk of anemia including gastrointestinal hemorrhage, iron deficiency, inflammation and infection, stress, and multiple b...

May 13th, 2022 - Background: For patients with severe upper gastrointestinal (UGI) hemorrhage, risk stratification for rebleeding or endoscopic hemostasis has been based on visually defined endoscopic stigmata of hemorrhage for more than 40 years. These are imperf...

Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...

Mar 31st, 2022 - Title: The efficacy of hemostatic powder TC-325 versus standard endoscopic treatment for gastrointestinal bleeding from malignancy; a multi-center randomized trial Background: Gastrointestinal (GI) bleeding arising from malignant tumors is increas...

Jun 1st, 2022 - NEW YORK (Reuters Health) - Females on the liver transplant waiting list are disadvantaged by the sodium-adjusted Model for End-stage Liver Disease score (MELDNa) currently employed to guide allocation decisions, but a sex-adjusted MELDNa score wo...

Oct 6th, 2021 - The ovarian cancer armamentarium continues to evolve with novel agents, such as antibody-drug conjugates (ADCs) and immunotherapy, even with clinical trial findings showing mixed, yet intriguing, results with these classes of agents. In a prese...

Aug 18th, 2021 - For patients with mantle cell lymphoma (MCL) who have progressed after treatment with a BTK inhibitor such as ibrutinib (Imbruvica), there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal ou...

Apr 21st, 2021 - The novel T-cell–engaging bispecific antibody glofitamab (RO7082859) demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive...

Dec 20th, 2020 - Nicholas J. Vogelzang, MD Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO’s annual meeting. The fatalities had not been reported with the c...